22 results about "Left Ventricle Remodeling" patented technology

The application discloses a kind of short peptides simulating RhoE C end, derivative and its pharmaceutical use in treating ventricular remodeling, belong to biological medicine technical field.The short peptide and derivative contain RhoE C end 200-240 linear function domain, can be combined and activated WWP2, remove HGS self-inhibition, start endosome-lysosome degradation pathway.Short peptide sequence is as SEQ ID NO.1, derivative can be coupled with TAT, T7 or RVG membrane penetrating peptide (SEQ ID NO.2-4), and endocytosed to myocardial cell by caveolin high efficiency delivery.The application solves the defects that existing anti-ventricular remodeling drug inhibits protective autophagy flow, and the ability of eliminating toxic protein is limited, can efficiently eliminate damaged mitochondria and misfolded protein, inhibits myocardial hypertrophy, fibrosis, improves cardiac remodeling, provides safe and effective treatment strategy for related diseases.

The invention discloses a motion intervention heart failure repair method based on Lgmn signal regulation and control, and relates to the technical field of heart failure treatment. According to the method, through aerobic exercise training (AET) with specific parameters, expression of Legumain (Lgmn) genes in macrophages is regulated in a targeted mode, the interburial effect of the macrophages is enhanced, then cell communication between the macrophages and cardiac muscle cells is enhanced, removal of the vertical death cardiac muscle cells is promoted, myocardial fibrosis and inflammatory response are relieved, and the effect of treating myocardial fibrosis is achieved. Finally, ventricular remodeling and heart functions of chronic heart failure (CHF) mice are improved. Experimental verification shows that the exercise intervention method can significantly improve the left ventricular ejection fraction (LVEF) and shortening fraction (FS) of CHF model animals, reduce the left ventricular end-of-systole inner diameter (LVESD), reduce myocardial cell apoptosis and necrosis, and promote inflammation regression. Drug intervention is not needed, safety is high, operation is easy and convenient, and a new effective way is provided for clinical rehabilitation treatment of heart failure.

The invention provides a heart implant, a delivery assembly and a heart implant system.The heart implant comprises a valve prosthesis and an anchoring nail, the anchoring nail can nail the valve prosthesis on a native tissue of an atrioventricular valve, on one hand, anchoring of the valve prosthesis in the heart is achieved, the problems of falling, shifting, twisting and the like of the valve prosthesis are avoided, and the heart implant delivery efficiency is improved; on the other hand, the compression of the valve prosthesis on the native tissue of the heart is greatly reduced so as to solve a series of problems such as ventricular structure remodeling caused by the valve prosthesis anchored through radial force, and on the other hand, the fitting gap between the valve prosthesis and the native tissue can be reduced, the sealing performance of the perivalvular is improved, the perivalvular leakage is reduced, and the heart safety is improved. On the other hand, when the valve prosthesis is nailed on the valve ring of the atrioventricular valve through the anchoring nail, the valve prosthesis is allowed to have a small axial height, and therefore the height of the valve prosthesis below the valve is reduced, and blocking of the valve prosthesis to blood entering the ventricular outflow tract is reduced.

The application discloses a traditional Chinese medicine composition for treating dilated cardiomyopathy, relates to the field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for improving ventricular remodeling of a dilated cardiomyopathy patient, which is prepared from the following traditional Chinese medicines in parts by weight: radix astragali 60-90 parts, semen platycladi 15-30 parts, cortex mori 15-30 parts, ramulus cinnamomi 10-15 parts, zingiberis rhizoma siccum 10-15 parts, curcuma zedoaria 10-20 parts, cinnamomum cassia 6-10 parts and euonymus alatus 10-15 parts. The application has remarkable advantages in improving heart failure symptoms of the DCM patient, reversing ventricular remodeling, improving exercise tolerance, controlling arrhythmia and improving long-term prognosis of the patient.

The invention relates to the field of biological medicine, in particular to a si-RNA composition for inducing cardiac fibroblasts to transdifferentiate into endothelial cells and application of the si-RNA composition. The si-RNA composition comprises a si-RNA (Ribonucleic Acid) aiming at a gene Huwe1, a si-RNA aiming at a gene Ltbp3, a si-RNA aiming at a gene Dysf and a si-RNA aiming at a gene Hivep3. The HLDH (Huwe1, Ltbp3, Dysf and Hive3) combined knockout can be used for successfully inducing the transformation of fibroblasts into endothelial cells in an in-vitro ischemia and hypoxia state. A carrier containing shRNA capable of expressing and generating the si-RNA composition is delivered into the heart, so that cardiac fibroblasts undergo transdifferentiation in vivo and participate in angiogenesis, and therefore, increase of fibrosis area and adverse ventricular remodeling after myocardial ischemia are limited through ways such as fibrosis remodeling, the heart function is retained, and myocardial ischemia is improved and repaired.

Methods and materials for treating chronic cardiac disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) to treat hypertrophic cardiomyopathy and other cardiac conditions, such as conditions associated with ventricular hypertrophy, atrial hypertrophy, ventricular remodeling, atrial remodeling, systolic and / or diastolic dysfunction, heart failure (e.g., heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction), and other forms of chronic heart disease (e.g., Fabry disease, Noonan syndrome, Pompe disease, PRKAG2-related cardiomyopathy, Danon disease, Friedrich ataxia cardiomyopathy, amyloidosis, or desminopathy) are provided herein.

The invention discloses a function and application of a lysine deficiency type protein kinase 2 inhibitor in inhibition of ventricular remodeling, and belongs to the field of functions and application of genes. According to the invention, the mutual relation between the expression of the WNK2 and the ventricular remodeling is determined, and the research result shows that the expression of the WNK2 is obviously improved compared with that of a normal group in a model with pathological ventricular remodeling; the ventricular remodeling including cardiac hypertrophy, fibrosis and heart function decline is remarkably relieved by inhibiting the expression of the WNK2, and the ventricular remodeling process is remarkably intensified and the heart function is deteriorated by promoting the overexpression of the WNK2. The WNK2 can be used as a drug target and used for screening drugs for protecting heart functions, resisting myocardial fibrosis and / or preventing, relieving and / or treating ventricular remodeling and related heart diseases, and an inhibitor of the WNK2 can be used for developing drugs for protecting heart functions, inhibiting ventricular remodeling and preventing, relieving and / or treating ventricular remodeling related diseases. And an effective new way is provided for clinical treatment of ventricular remodeling.

This invention discloses the application of a Trichinella spiralis cysteine ​​protease inhibitor in acute myocardial infarction and subsequent ventricular remodeling, belonging to the field of medicinal chemistry. This invention provides a drug that can prevent, alleviate, and / or treat acute myocardial infarction and subsequent ventricular remodeling. The active ingredient of this drug is the Trichinella spiralis cysteine ​​protease inhibitor cystatin, abbreviated as rTs-Cys. rTs-Cys can effectively delay acute myocardial infarction and inflammatory response in mice, reduce the infarct area, improve cardiac function deterioration, and reverse organ pathological damage, providing a new approach for the clinical treatment of acute myocardial infarction and subsequent ventricular remodeling.

The invention provides a traditional Chinese medicine composition for treating heart failure and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following components: 1-12 parts of rohdea japonica, 1-12 parts of codonopsis pilosula, 1-12 parts of astragalus membranaceus, 1-12 parts of cassia twig, 1-8 parts of bighead atractylodes rhizome, 1-12 parts of poria cocos, 1-12 parts of radix ophiopogonis, 2-14 parts of semen lepidii, 1-10 parts of radix aconiti lateralis preparata, 1-10 parts of schisandra chinensis, 1-12 parts of hairyvein agrimony, 1-10 parts of pseudo-ginseng, 1-12 parts of epimedium, 1-12 parts of leonurus, 1-10 parts of ligusticum wallichii, 2-14 parts of salvia miltiorrhiza, 2-12 parts of radix sophorae flavescentis and 1-8 parts of liquorice. The traditional Chinese medicine composition can enhance myocardial contractility, increase coronary artery blood flow volume, protect myocardial cells, improve heart functions, obviously improve the heart functions and left ventricular remodeling, discharge liquid retained at the time of heart failure, relieve the pre-load of the heart and relieve edema; load during cardiac contraction is reduced, and excessive work of the heart is avoided.

The invention relates to the technical field of biological medicines, and particularly discloses application of sarcosine in preparation of a medicine for treating ischemic heart disease. According to the technical scheme provided by the invention, the expression of HIF1-alpha protein can be remarkably increased through sarcosine, so that angiogenesis is enhanced, the heart function of the ischemic heart disease is improved, ventricular remodeling is relieved, and the ischemic heart disease can be effectively prevented and / or treated.

The invention relates to the technical field of biological medicine, in particular to application of glucosylceramide level as a diagnosis and treatment target of heart failure. According to the invention, key pathological cascade reactions such as lysosomal membrane permeabilization, cathepsin leakage, mitochondrial dysfunction and the like in the occurrence and development process of heart failure are blocked from the source by reducing the level of glucosylceramide in myocardial tissues. By inhibiting synthesis of glucosylceramide or enhancing degradation in lysosome of glucosylceramide, glucosylceramide abnormally accumulated in myocardial cells is removed, organelle structures and energy metabolism states are remarkably improved, and then myocardial contraction and relaxation functions are improved. In an animal model, the strategy can reverse ventricular remodeling, improve ejection fraction and relieve cardiac hypertrophy and fibrosis. In addition, the glucosylceramide detection method provided by the invention can be used for assisting in evaluating metabolic abnormalities related to heart failure, so that disease judgment is more accurate.

The invention discloses a preparation method of a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating hypertrophic cardiomyopathy, and belongs to the technical field of traditional Chinese medicines. The technical problem to be solved is to provide the traditional Chinese medicine for treating dilated cardiomyopathy, atherosclerotic plaque, myocardial fibrosis, ventricular remodeling, senile cardiac metabolic disorder, hypertrophic cardiomyopathy, hypertrophic cardiomyopathy and hypertrophic cardiomyopathy aiming at the defects of the prior art in preparation of medicines for preventing and treating hypertrophic cardiomyopathy. The invention also discloses application of the traditional Chinese medicine composition in preparation of medicines for treating hypertrophic cardiomyopathy, wherein the traditional Chinese medicine composition has the effects of improving cardiac degeneration of mice with myocardial hypertrophy induced by blood constriction. According to the key point of the technical scheme, the invention provides the application of the traditional Chinese medicine composition in preparing the medicine for preventing and treating hypertrophic cardiomyopathy. The traditional Chinese medicine composition comprises the following raw materials: American ginseng, ginseng, astragalus membranaceus, spina date seeds, salvia miltiorrhiza, pseudo-ginseng, fingered citron and mangnolia officinalis.

The application discloses a kind of adipose tissue-derived mitochondrial-derived vesicles and its preparation method and application, belong to the field of biological medicine.The preparation method includes obtaining mouse adipose tissue, including at least one of interscapular brown adipose tissue, epididymal white adipose tissue, beige adipose tissue, in vitro cultured adipocyte;Mouse adipose tissue homogenate is removed by differential centrifugation Unbroken cell, nucleus, mitochondrial and organelle precipitate, the supernatant obtained is treated by trypsin and then ultracentrifuged, the precipitate is collected, washed, to obtain mitochondrial-derived vesicles, which are membrane-coated vesicles, with a particle size of 100-200 nm, enriched in mitochondrial membrane proteins and oxidative phosphorylation-related proteins, and proved by ischemic heart disease model that it can improve heart function, reduce the degree of ventricular remodeling in mice with ischemic heart disease and reduce the fibrosis area, for the preparation of drugs for preventing or treating ischemic heart disease, and has important clinical application value.

The invention discloses an external medicine for relieving myocardial ischemia and improving ventricular remodeling. The preparation with the functions of relieving myocardial ischemia and improving ventricular remodeling is prepared for the first time, it is clear that the preparation has the excellent treatment effect through cell experiments and animal experiments, in a mouse MI model, the medicine can obviously improve echocardiogram cardiac contraction and diastole indexes, and the application range is wide. The inflammatory cell infiltration of myocardial infarction model mice is obviously reduced, so that the preparation is proved to be capable of relieving and treating myocardial ischemia-related disease symptoms.

The application discloses functions and application of lysine-deficient protein kinase 2 inhibitors in inhibiting ventricular remodeling, and belongs to the field of gene functions and application.The application determines the interrelation between the expression of WNK2 and ventricular remodeling, and the research result shows that in a model of pathological ventricular remodeling, the expression of WNK2 is significantly higher than that of a normal group;inhibition of WNK2 expression significantly reduces ventricular remodeling including myocardial hypertrophy, fibrosis and heart function reduction, and promotion of WNK2 overexpression significantly aggravates the ventricular remodeling process and worsens heart function.WNK2 can be used as a drug target for screening drugs for protecting heart function, resisting myocardial fibrosis and / or preventing, relieving and / or treating ventricular remodeling and related heart diseases, and an inhibitor of WNK2 can be used for developing drugs for protecting heart function, inhibiting ventricular remodeling and preventing, relieving and / or treating diseases related to ventricular remodeling, thereby providing an effective new approach for clinical treatment of ventricular remodeling.

This invention belongs to the field of regenerative medicine technology, specifically relating to bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1, their preparation method, and applications. The steps are as follows: Primary mouse bone marrow mononuclear precursor cells are cultured in expansion medium for 7 days to obtain macrophages, with the medium changed every 2-3 days during this period; on the 7th day, the expansion medium is replaced with a high-efficiency induction medium and cultured for 46-50 hours to obtain bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1. This invention, through a time-series strategy of TGF-β pre-induction combined with IL-4 / IL-5 / IL-13 synergistic induction, can significantly enhance the expression levels of CD301b, TIMD4, and LYVE-1 in BMDM, making their function close to that of natural cardiac resident macrophages, and effectively exerting anti-inflammatory, repair-promoting, and ventricular remodeling-inhibiting effects after AMI.

This invention relates to the field of nanomaterial preparation technology, and particularly to a targeted nanozyme with catalytic antioxidant activity, its preparation method, and its applications. The targeted nanozyme with catalytic antioxidant activity provided by this invention comprises Ru / LDH nanosheets and a myocardial targeting peptide; the myocardial targeting peptide is covalently coupled to the surface of the Ru / LDH nanosheets via DSPE-PEG-COOH; the Ru / LDH nanosheets comprise layered double metal hydroxide LDH and Ru introduced by etching and dispersed in a single-atom manner. The targeted nanozyme provided by this invention exhibits multi-enzyme synergistic activity, acid stability, and pathological myocardial targeting, and can be used for the treatment of oxidative stress-related cardiovascular diseases such as diabetic cardiomyopathy. The targeted nanozyme provided by this invention has good biocompatibility and safety, can target cardiac lesions, reduce oxidative damage, inhibit fibrosis and ventricular remodeling, and promote cardiac function recovery.

The application provides application of a traditional Chinese medicine composition in preparation of a medicine for treating cardiac senility, and the traditional Chinese medicine composition is composed of Semen Euryae, Fructus Lycii, Schisandra chinensis, Cnidium, Chamaerops, Semen Allii Tuberosi, Dipsacus asper, Cistanche, Rehmannia glutinosa, Cyathula officinalis, Herba Epimedii, Rubus chingii, Ginseng, Cornu Cervi Pantotrichum, sea horse and Fructus Meliae Toosendan. Test results show that the medicine can significantly reduce the collagen content of myocardial tissue of HFpEF rats, reduce the degree of myocardial fibrosis, inhibit left ventricular remodeling, thereby improving the cardiac function of the rats, preventing and treating heart failure with preserved ejection fraction, and treating cardiac senility with remarkable effects.

The application relates to the field of biological medicine, and provides application of OpiCa1 mutant peptide DE-4A in antagonizing heart failure after myocardial infarction. Experiments prove that the polypeptide DE-4A can remodel myocardial calcium homeostasis by restoring RyR2 protein stability and blocking excessive activation of the CaMKII signal pathway. This mechanism effectively reduces myocardial injury and fibrosis, significantly improves ventricular remodeling and heart dysfunction after myocardial infarction, and provides new experimental evidence for the treatment of ischemic cardiomyopathy. DE-4A has the effects of improving myocardial contractile function, regulating Ca 2+ homeostasis, which may be a key link in the pharmacodynamic mechanism, and provides new experimental evidence for the treatment of ischemic heart disease.

The invention relates to an application of overexpressed NLRC3 in treating right ventricular (RV) remodeling caused by pulmonary arterial hypertension (PH), in particular to an AAV vector of overexpressed NLRC3 by adopting myocardial in-situ injection and / or tracheal instillation, or Treg cells of in-vitro overexpressed NLRC3 by adopting adoptive transfer. Verification shows that in the RV reconstruction process, the number of Treg cells is rich, and the Treg cells are crucial to reduction of harmful effects of RV reconstruction; the RV Treg cells show remarkable regional heterogeneity and compensatory characteristics, which are related to the NLRC3 level, mainly because the inactivation of the NLRC3-JAK2 / STAT4 pathway promotes the down-regulation of the Th1-Treg cells and weakens the immunosuppression function of the RV Treg cells; the RV remodeling can be aggravated by NLRC3 defects, RV dysfunction and failure are caused, RV remodeling is remarkably inhibited by the NLRC3 overexpressed Treg cells, and a new treatment strategy is provided for precise immunoregulation of RV remodeling caused by PH.

The application discloses an animal model construction method simulating human ischemic heart failure, and relates to the field of biomedical experimental animal models, and comprises the following steps: S1, model construction: embolism suspension liquid containing microspheres with a specific diameter is injected into the left ventricular cavity of a target animal through percutaneous puncture, so that the microspheres are embolized in myocardial microvessels through coronary artery circulation, thereby establishing a coronary artery microembolism model; S2, early screening: within 24 hours after model construction, cardiac ultrasound detection and serum biomarker detection are performed on the target animal; the animal model construction method simulating human ischemic heart failure simulates embolism of human myocardial arterioles and capillary arterioles by controlling the particle size (15-45 mu m) of the microspheres, induces diffuse myocardial ischemia closer to the clinic, thereby stably leading to progressive ventricular remodeling and chronic heart failure, rather than acute transmural infarction.